Blog2018-10-06T15:07:36+00:00

Blog

Bitte beachten Sie: unsere Fachbeiträge sind auf unserer Wissensdatenbank für klinische Forschung „CliNFo.EU“ veröffentlicht.
Bei Klicken auf einen Artikel werden Sie dorthin umgeleitet.

GKM und interActive Systems: Software für open.med

GKM und interActive Systems: Software für open.med

GKM und interActive Systems: Software für open.med Damit die medizinische Behandlung und die soziale Beratung der open.med-Patient(inn)en besser dokumentiert werden können, haben die GKM Gesellschaft für Therapieforschung mbH und der Berliner EDC Software Provider interActive Systems für Ärzte der Welt eine eigene Software entwickelt.
Vom Aussterben bedroht – gefährdet der Brexit klinische Prüfungen in UK?

Vom Aussterben bedroht – gefährdet der Brexit klinische Prüfungen in UK?

Aktuell laufen ca. 1.500 klinische Studien in verschiedenen EU Mitgliedsstaaten, deren Sponsoren ihren Sitz in UK haben. Schätzungen zu Folge werden 50 % dieser Studien auch nach dem Austritt Großbritanniens aus der Europäischen Union (BREXIT) am 30. März 2019 weiterlaufen. In diesem Zusammenhang stellt sich unweigerlich die Frage: Wie geht es mit den klinischen Prüfungen und der Zusammenarbeit mit UK nach dem Brexit weiter?
The Art of Storytelling in Clinical Research, or: Adverse Event Narratives and their Pitfalls

The Art of Storytelling in Clinical Research, or: Adverse Event Narratives and their Pitfalls

In Clinical Study Reports (CSR), a short description (“narrative“) of all Serious Adverse Events (SAE) must be provided. In addition, all Adverse Events (AEs) leading to discontinuation, and AEs of special interest, must be included. Such narratives should provide a concise yet comprehensive overview of each case [...]
Mit Kontinuität in die Zukunft - Änderungen vor und hinter den Kulissen

Mit Kontinuität in die Zukunft - Änderungen vor und hinter den Kulissen

Sehr geehrte Partner der GKM, die Grundbausteine für eine gute und langjährige Zusammenarbeit sind nach unserer Überzeugung Vertrauen und Kontinuität. Mit diesen Werten konnten wir, Siegfried K. Hippe und Renate E. Hippe, die GKM seit ihrer Gründung im Jahre 1981 zusammen mit einer wachsenden Zahl an motivierten Mitarbeitern zu einer international agierenden CRO entwickeln.
Die klinische Bewertung nach der neuen MDR – de facto Pflicht zur klinischen Prüfung

Die klinische Bewertung nach der neuen MDR – de facto Pflicht zur klinischen Prüfung

Die Neuregelungen der MDR zur klinischen Bewertung werden künftig dazu führen, dass deutlich mehr klinische Daten zu den eigenen Medizinprodukten des Herstellers vorliegen müssen als bisher, um im Rahmen der klinischen Bewertung klinische Evidenz mit den grundlegenden Sicherheits- und Leistungsanforderungen zeigen zu können [...]
Intention-To-Treat (ITT) vs. Per-Protocol (PP) analysis: what to choose?

Intention-To-Treat (ITT) vs. Per-Protocol (PP) analysis: what to choose?

Differences between and characteristics of the Intention-To-Treat (ITT) vs. Per Protocol (PP) principles: which is the method of choice for the primary analysis of your clinical trial?
Arzneimittelzulassung vs. frühe Nutzenbewertung – die Unterschiede

Arzneimittelzulassung vs. frühe Nutzenbewertung – die Unterschiede

Häufig gibt es Diskrepanzen zwischen den Designanforderungen der Zulassungsbehörden und der Anforderungen an Studien für die Herleitung eines Zusatznutzens nach §35a SGB V. Die Eignung einer klinischen Studie als Basis für eine Arzneimittelzulassung bedeutet nicht zwangsläufig, dass diese Studie auch für die Bewertung eines Zusatznutzens geeignet ist [...]
A hitchhiker’s guide to data review in an ongoing (“live”) study – part 2: data review for interim analysis

A hitchhiker’s guide to data review in an ongoing (“live”) study – part 2: data review for interim analysis

If you are thinking of a clinical trial, you might ask yourself why and how data review for interim analysis can be a topic for a whole article. However, in a non-interventional study there are certain challenges [...]
The end of the eCRF in local language? Workflows for meeting local and global demands in your non-interventional study (NIS)

The end of the eCRF in local language? Workflows for meeting local and global demands in your non-interventional study (NIS)

What aspects do you need to consider when planning a multi-lingual eCRF? Are regulatory requirements effective 22 November 2017 a cut-off date for the future of eCRFs in local language?
Why the value of on-site monitoring cannot be challenged by remote/ centralized monitoring

Why the value of on-site monitoring cannot be challenged by remote/ centralized monitoring

This is not to say we should do as we always did. This is also not to promote unnecessarily frequent monitoring visits or a 100% source data verification (SDV). However, in times were risk-based quality management including centralized monitoring are in the regulatory focus, I feel we forget to reflect the undeniable value that on-site monitoring can give to a clinical study [...]
A hitchhiker’s guide to data review in an ongoing (“live”) study – part 1: data review for pharmacovigilance purposes

A hitchhiker’s guide to data review in an ongoing (“live”) study – part 1: data review for pharmacovigilance purposes

In a way, data review for pharmacovigilance purposes is the simplest and yet most demanding kind of data review, as time is a pressing matter in this context. The data are reviewed in different time frames according to the potential risks that arise from them [...]
Wir haben es getan! </br>Warum eine CRO ihrem Verband beitreten sollte.

Wir haben es getan!
Warum eine CRO ihrem Verband beitreten sollte.

BVMA oder nicht BVMA. Der Bundesverband Medizinischer Auftragsinstitute e.V. (BVMA) gilt als die Interessenvertretung der Auftragsforschungsinstitute (Contract Research Organisations, CRO) in Deutschland. Die Frage, ob GKM sich um eine Mitgliedschaft bemühen sollte [...]
Ärzte der Welt open.med goes online

Ärzte der Welt open.med goes online

Ärzte der Welt e.V. bietet in Deutschland seit über zehn Jahren Menschen, die keinen oder nur einen eingeschränkten Zugang zum Gesundheitssystem haben, kostenlose medizinische Versorgung und Beratung an. GKM Gesellschaft für Therapieforschung mbH unterstützt das Projekt open.med in der online Lösung der Patientenakte.
What to consider when planning the sample size for a non-interventional study

What to consider when planning the sample size for a non-interventional study

The determination of an "adequate" sample size is an essential part of the statistical planning process. Depending on your type of non-interventional study design and your specific study objectives, there are different approaches for the planning of your sample size [...]
Acting out? Points to consider when planning to involve actigraphy measurements into your study design

Acting out? Points to consider when planning to involve actigraphy measurements into your study design

From a medical perspective, addressing concepts of physical activity and activity capacity, vital signs (like heart rate or blood pressure), and/or sleep quality in a real-time manner rather than a snap-shot at a visit, make perfect sense and could enrich the value story of novel therapies. However, when planning to involve actigraphy measurements into your study design, there are several points to be considered, including issues of validity, data transfer and data analysis [...]
Don't panic: It's only the Simpson's Paradox

Don't panic: It's only the Simpson's Paradox

Your results on the overall patient level contradict results on the subgroup level? There is no need to panic. With a deeper look into the data, one can get to the bottom of this observation. [...]
Das Bewertungsverfahren für Medizinprodukte: erste Erkenntnisse und Empfehlungen

Das Bewertungsverfahren für Medizinprodukte: erste Erkenntnisse und Empfehlungen

Für welche Medizinprodukte ist die Bewertung relevant, wie läuft das Bewertungsverfahren ab und welche Lehren kann man aus den bisherigen Verfahren ziehen? [...]
Verpflichtung zur klinischen Nachbeobachtung (PMCF) von Medizinprodukten

Verpflichtung zur klinischen Nachbeobachtung (PMCF) von Medizinprodukten

Die klinische Bewertung ist fortan während des gesamten Lebenszyklus des Medizinprodukts anhand von klinischen Daten zu aktualisieren, die aus der klinischen Nachbeobachtung und der Überwachung nach dem Inverkehrbringen stammen.
SAE reporting in the age of digitalisation (eSAE)

SAE reporting in the age of digitalisation (eSAE)

The use of electronic data capture (EDC) and electronic case report forms (eCRF) is becoming the gold standard in clinical research. Today, the dream of a paperless (or at least near-paperless) study seems within reach [...]
User-friendly eCRF-design: the key for successful data collection

User-friendly eCRF-design: the key for successful data collection

To ensure a perfectly suited eCRF design many different aspects have to be taken into account also with regard to user-friendliness [...]
The “Do’s and Don’ts” when searching clinical trials registers

The “Do’s and Don’ts” when searching clinical trials registers

Searching clinical trial registers is a “must have” in clinical research and evidence based medicine. However, the different registers have their unique characteristics and there are several issues to be kept in mind when searching clinical trial registers, especially when the standards of evidence based medicine need to be fulfilled [...]
Stuck in the middle – mean vs. median

Stuck in the middle – mean vs. median

The mean value of numerical data is without a doubt the most commonly used statistical measure. Anyone who has a basic statistical background knows how to calculate the (arithmetic) mean. However, sometimes the median is used as an alternative to the mean. [...]
Precision medicine clinical trials - How far are we in personalized medicine?

Precision medicine clinical trials - How far are we in personalized medicine?

Using precision medicine as an aid to plan clinical trials catches much attention in the present era of drug development. Several innovative precision medicine initiatives have launched clinical trials for complex diseases.
Precision medicine clinical trials - How far are we in personalized medicine?

Precision medicine clinical trials - How far are we in personalized medicine?

Using precision medicine as an aid to plan clinical trials catches much attention in the present era of drug development. Several innovative precision medicine initiatives have launched clinical trials for complex diseases.
Inform to engage: 4 reasons why patient centricity is not just a buzz word

Inform to engage: 4 reasons why patient centricity is not just a buzz word

patient centricity

“The study was terminated due to poor rates of recruitment, continuation, and engagement.” Or as the academic would say: “The trial did not reach sufficient statistical power.”

Unfortunately, the worst case scenario of early termination of a project is not uncommon in clinical research.

Clinical trials as well as non-interventional studies (NIS) fail to reach meaningful results simply because too little patients/ subjects take part in the study in the first place, or too many violate the therapy scheme, leave questionnaires untouched, or suddenly decide to leave the study.

But why is that? You will agree that patients do not “break the rules” out of spite.

In the end, the ultimate motif for participation may become irrelevant if you, as a patient, do not feel taken seriously, included, represented, involved or informed.

Have you ever taken part in a clinical or observational study yourself? Even if not, find yourself in the position of the patient: Why would you like to be part of a clinical research project?

It might be the chance to receive (better) treatment, or because your doctor recommended you to do so, or your personal aspiration to drive medical research for your indication.

In the end, the ultimate motif for participation may become irrelevant if you, as a patient, do not feel taken seriously, included, represented, involved or informed. Then, uncertainty or uneasiness (with regard to your health or data privacy!) quickly leads to discontinuation.

Put the patient in the center of every decision you make!

You want truly engaged patients for your study? Then put them in the center of every decision you make!

Your endpoints represent your patients’ preference; your study design goes hand in hand with the medical condition, medical care and life situation of your patients; and your study material takes your patients by the hand and informs them at every step of the project about what, when, how and why.

For successful patient engagement keep information high and live patient centricity throughout your study.

How? Let’s explore some approaches by having a closer look at 4 reasons why patient centricity is not just a buzz word.

1. The patient information is a comprehensive instruction manual customized for the patient

I will not give you a medical writing lecture or go into banalities like “Keep it short and simple”. Rather, I would like to shift the focus away from the “how” towards the “what”, i.e. the content of the patient information.

It is important to realize that the patient information is not just an obligatory document requested by the ethics committees. In contrast, it is a crucial study document when it comes to patient engagement and should be appreciated as a chance to get in contact with the patients and make them feel fully informed and certain about their decision for (or against) participation.

As such, the patient information also does not need to be written for the ethics committees (even if available templates are provided by them). It must be written for the patient!

It might seem like a triviality but still I would like to stress that the patient information should be customized for the patient.

While writing the patient information, be fully aware of critical details of your study like e.g.

  • the age of your patient population

  • restrictions of comprehension that might come with the medical condition of your patients,

  • the complexity of the therapy scheme or of the visits schedule in your study,

  • or the potential risks that your patients must be fully aware of.

On the one hand, language and vividness of the text must be adapted accordingly.

On the other hand, make sure that your patients can clearly follow the argumentation on why this study is performed, the design of the treatment scheme (placebo/ comparator/ investigational drug, frequency, etc.), the schedule of the medical visits, the performed examinations and questionnaires in use, and the potential benefit and risks that might come with the participation in the study.

Engagement and continuity only comes with full understanding and confidence in the procedure.

The patient information is not a report or procedure protocol simply listing what is done first, next, last. It is a well-structured, clearly phrased and comprehensibly argued instruction manual.

Do not hesitate to make use of illustrations, figures, and tables to support transparency and understanding for the patient. Even if the template you are using does not stipulate such “gimmicks” – the gimmicks may help your patient to understand the study and to adhere to a given regime.

After reading the document, there should be no questions left on the study process. Engagement and continuity only comes with full understanding and confidence in the procedure.

2. The choice of clinical endpoints matches the patient preference

The choice of endpoints must, of course, comply with regulatory guidelines. However, in addition to the regulatory accordance, the patients’ preferences and input should be incorporated.

When designing a clinical project and deciding for the clinical endpoints to be examined in a study, frequently the choice is based on the symptoms’ strength of the study indication. While this approach provides you with an organized list of potential endpoints sorted by the symptoms’ severity, the preference of the patient might fall behind.

That is, a rather predominant phenotype for the patient might not necessarily represent a regulatory-relevant endpoint.

A rather predominant phenotype for the patient might not necessarily represent a regulatory-relevant endpoint.

In contrast, a possibly easily measurable parameter must not coincidentally be an important measure for the patient. This might be particularly true for paraclinical measures like lab values or imaging results. Although the patient can be informed about and be aware of the importance of such a parameter, other conditions might be of greater impact for the patient.

Especially when side effects appear, the patient might revise his judgment on the relevance of certain measures in comparison to the then naturally much more important symptoms.

Thus, in order to come up with truly patient-relevant endpoints, I recommend considering the conduction of a patient preference study in the run-up of your (interventional) clinical project. This gives you the chance to get to know much better your patient population and its preferences upfront.

Why not ask the patients upfront if these values actually matter to them?

Once you are aware of the challenges and restrictions the patients are facing, you can plan your study accordingly. This applies not only to the choice of endpoints but to the study design in general.

This sounds trivial? Try to find a real evidence – not eminence (!) – based proof in the literature that lymphocyte count or splenomegaly represent relevant impacts on the patient with chronic lymphocytic leukemia. Not so easy, right?

So why not ask the patients upfront if these values actually matter to them? Or let’s rephrase the question: Wouldn’t you be more engaged in a study where you know that fellow patients have participated in the design and/or endpoint creation?

3. The study design is based on the patient’s condition with respect to indication, care and everyday life

In the same way as preferences and needs of the patient should lead your decision on study endpoints and patient information structure, they should also be in focus when it comes to the design of your study’s infrastructure, organization and schedule.

How does the medical condition influence the everyday life situation of the patient? What are the patient’s restrictions? What are his/her preferences and needs with respect to medical visits? Is the patient able to go down to a site or would it rather be suitable to think about transport services, visits at the general practitioner, home visits or a remote visit (site-less) approach?

Indeed, 55% percent of people rate the location of the site as the most decisive factor for/against the participation in a clinical trial1. Thus, a patient centered study-site-design can be of great benefit for study recruitment and continuation.

The basis for such new study designs – digital technologies, wearables, sensors and apps – do exist; also their acceptance and usage increases continuously.

Approaches like the so called “hybrid studies”, where patients have the choice between a classical site-visit and a remote visit via, for example, a digital platform, might incorporate the preferences of a much broader patient population and boost patient engagement.

The basis for such new study designs – digital technologies, wearables, sensors and apps – do exist; also their acceptance and usage increases continuously.

In Germany, for example, today 58 million people use the internet; 34.6 million of those are over 40 years old. Within the last three years, 4.4 million people over 50 years joined in. The number one device in use is the smartphone (66%)2.

Also healthcare apps and fitness trackers are on the up: in Germany, 28% of the internet users utilize such technologies on a daily basis, and of those only 31% are between 15 and 19 years while 30% are aged 60 years or older3.

Study designs that support the individual preferences will recruit and retain patients in the long run.

Thus, the widespread prejudice that digital technologies are only for the young patient population is simply wrong. I would rather argue for a personal preference, independent of age.

Thus, study designs that support the individual preferences and needs of the patient will recruit and retain patients in the long run.

But with all appreciation for the new technologies: please don’t use them with might and main just because they are trendy and hip. Always consider also the clinical routine and the usefulness of the application.

For example, using e-questionnaires on tablets at chemotherapy sites might sound fancy and reasonable in the first place. However, if certain sites don’t follow the protocol and patients are handed the tablets after receiving the treatment (that commonly coincides with a great discomfort), patient engagement might naturally equal zero and/or the patient reported outcome might simply give a wrong picture. A paper questionnaire that can be filled in at home or an e-questionnaire that can be filled in at home via a certified app might be a better solution.

4. Updates on the course of the study keep the patient informed

As a last reason why patient centricity is not just a buzz word, I would like to bring up the study material that is provided to the patient throughout the study. Thereby, it makes no difference whether this information is passed out by the physician at the sites or can be downloaded by the patient from a study platform or is sent to the patient via a mobile app onto his smart phone.

By providing the patient with regular updates on the study progress you show appreciation for his participation.

Also, by informing you can prevent the feeling of potential uncertainty about whether the study is still running, whether the patient’s data is of any use or value, whether the project is still on time et cetera.

Once your study has been completed, let the participants know about the next steps: What happens with their data? What is it used for? Will it be published? Of course there will be also interest in the results of the study. How can you make sure that the participants will get to know the outcomes of your project? Is it really sufficient “appreciation” to direct the patient to the EudraCT or clinicaltrials.gov, or could tailored information materials about the study also increase your visibility and image in the patient community?

The key to a successful study engagement lies in listening and a change in perspective: the ones’ who the study is designed for in the first place.

An empowered patient who feels involved, informed and at the center of your clinical project, will automatically be more engaged and, thus, increase the quality of your data and study results.

In my opinion, the key to a successful study engagement lies in listening (and patient centricity is just a synonym for it) and a change in perspective: the ones’ who the study is designed for in the first place.

Picture: @Jérôme Rommé /Fotolia.com

  1. CISCRP 2015 Perceptions & Insights Study
  2. Digitaler Gesundheitsmarkt Report 2016
  3. GfK Global study: Health and fitness monitoring
  4. CISCRP 2015 Perceptions & Insights Study
  5. Digitaler Gesundheitsmarkt Report 2016
  6. GfK Global study: Health and fitness monitoring
Inform to engage: 4 reasons why patient centricity is not just a buzz word

Inform to engage: 4 reasons why patient centricity is not just a buzz word

For successful patient engagement keep information high and live patient centricity throughout your study. How? Let’s explore some approaches by having a closer look at 4 reasons why patient centricity is not just a buzz word.
Databases for systematic literature searches

Databases for systematic literature searches

Systematic literature searches are an essential tool of evidence based medicine and as such unavoidable in almost every part of medical research. Their aim is to identify as much available evidence regarding a specific scientific question as possible, by use of a focused, pre-defined and unbiased search strategy. [...]
Databases for systematic literature searches

Databases for systematic literature searches

Systematic literature searches are an essential tool of evidence based medicine and as such unavoidable in almost every part of medical research. Their aim is to identify as much available evidence regarding a specific scientific question as possible, by use of a focused, pre-defined and unbiased search strategy.
Warum Sie nicht auf die Verwendung eines Clinical Trial Management Systems (CTMS) verzichten sollten

Warum Sie nicht auf die Verwendung eines Clinical Trial Management Systems (CTMS) verzichten sollten

Um eine klinische Prüfung effizient managen zu können, benötige ich ein System, das es mir zu jeder Projektphase ermöglicht, Aufgaben und Aktivitäten zu planen, zu erfassen, zu kontrollieren sowie studienrelevante Dokumente zu verwalten. Nur, welches System ist dafür geeignet? [...]
How a Clinical Trial Management System (CTMS) can improve the quality of your study

How a Clinical Trial Management System (CTMS) can improve the quality of your study

As the coordinator or manager of a clinical trial, I have one simple goal: I want my clinical trial to be successful. However, to guarantee success, I need to be able to manage my project efficiently. But what system is suitable for this?
Warum Sie nicht auf die Verwendung eines Clinical Trial Management Systems (CTMS) verzichten sollten

Warum Sie nicht auf die Verwendung eines Clinical Trial Management Systems (CTMS) verzichten sollten

Um eine klinische Prüfung effizient managen zu können, benötige ich ein System, das es mir zu jeder Projektphase ermöglicht, Aufgaben und Aktivitäten zu planen, zu erfassen, zu kontrollieren sowie studienrelevante Dokumente zu verwalten. Nur, welches System ist dafür geeignet?
Choosing the right safety reporting workflow for your study

Choosing the right safety reporting workflow for your study

Safety comes first. Always. Especially in the clinical setting. Naturally and importantly, safety event reporting and pharmacovigilance are subject to severe regulatory oversight. Consequently - and here, I’m confident you will agree with me based on your own experience: When planning a clinical project, one of the most sensitive, and coincidentally most important issues, is the establishment of a secure, feasible, functional and effective safety reporting workflow [...]
Choosing the right safety reporting workflow for your study

Choosing the right safety reporting workflow for your study

Safety comes first. Always. When planning a clinical project, one of the most sensitive, and coincidentally most important issues, is the establishment of a secure, feasible, functional and effective safety reporting workflow.
Das neue Zauberwort: Risikobasiertes Qualitätsmanagement in der klinischen Forschung

Das neue Zauberwort: Risikobasiertes Qualitätsmanagement in der klinischen Forschung

Das voraussichtlich bis Mitte 2017 finalisierte Addendum der ICH-GCP Guideline hebt das Thema Risikomanagement in klinischen Prüfungen auf ein neues Niveau - die Umsetzung eines risikobasierten Qualitätsmanagements im Rahmen von klinischen Prüfungen bleibt nicht mehr lange der Entscheidung des Sponsors vorbehalten, sondern wird gesetzliche Pflicht […]
Risk-based quality management – the new magic phrase  in clinical research

Risk-based quality management – the new magic phrase in clinical research

The for mid-2017 expected final version of the ICH-GCP guideline addendum takes the subject risk management to the next level: the extent and implementation of a risk-based quality management for a clinical trial no longer remains within the judgement of the sponsor but actually becomes a legal obligation.
Das neue Zauberwort: Risikobasiertes Qualitätsmanagement in der klinischen Forschung

Das neue Zauberwort: Risikobasiertes Qualitätsmanagement in der klinischen Forschung

Das voraussichtlich bis Mitte 2017 finalisierte Addendum der ICH-GCP Guideline hebt das Thema Risikomanagement in klinischen Prüfungen auf ein neues Niveau - die Umsetzung eines risikobasierten Qualitätsmanagements im Rahmen von klinischen Prüfungen bleibt nicht mehr lange der Entscheidung des Sponsors vorbehalten, sondern wird gesetzliche Pflicht
35 Jahre GKM Gesellschaft für Therapieforschung mbH - im Spiegel der Kommunikations-Technologie

35 Jahre GKM Gesellschaft für Therapieforschung mbH - im Spiegel der Kommunikations-Technologie

So begann im Jahre 1981 die GKM Gesellschaft für Therapieforschung mbH der Pharmaindustrie ihre Dienste anzubieten. Jubiläen bringen mit sich, dass es Lob und gute Wünsche von allen Seiten gibt, das freut uns natürlich sehr. Es gibt aber auch Anlass zum Nachdenken und Zurückschauen. [...]
Learnings from clinical and non-interventional studies on psoriasis

Learnings from clinical and non-interventional studies on psoriasis

GKM’s „Lessons Learned” whitepaper series enters a second round. This time, we focus on psoriasis. We can rely on our experience in this field from 20 years and 21 clinical and non-interventional studies [...]
Om – und alles wird gut?

Om – und alles wird gut?

Digitalisierung der Medizin in Bayern – Fokus klinische Patientendaten“ - Der Veranstaltungsort, wie auch die prominente politische und akademische Besetzung, unterstreichen die Wichtigkeit und Aktualität dieses Themas [...]
A quick guide to your non-interventional study

A quick guide to your non-interventional study

Contrary to the outdated image of the non-interventional study (NIS) as a pure marketing instrument, this kind of study is particularly suitable for emphasizing the effectiveness, efficiency and safety of a drug under real life conditions. The following infographic serves as a quick guide for the planning of your NIS [...]
A quick guide to your non-interventional study

A quick guide to your non-interventional study

Contrary to the outdated image of the non-interventional study (NIS) as a pure marketing instrument, this kind of study is particularly suitable for emphasizing the effectiveness, efficiency and safety of a drug under real life conditions. A quick guide for the planning of your NIS.
Mücken für die Wissenschaft

Mücken für die Wissenschaft

Die Erforschung der Stechmücke wurde speziell in Deutschland lange Zeit vernachlässigt. Daher mangelt es heute, in Zeiten des Zika-Virus, der Globalisierung und der Klimaveränderung, an fundamentalem Wissen über das Vorkommen, die Verbreitung und die Biologie der verschiedenen Mückenarten. Wir rufen Sie daher zur Mückenjagd auf [...]
Scientific and Medical Communication Today

Scientific and Medical Communication Today

This year’s EMWA symposium in Munich provided an excellent overview on the diverse and fast-changing world of medical writing. Far from dealing only with dry and difficult matters, as outsiders might suspect, medical writing essentially revolves around all shades of effective communication in the world of medicine [...]
Statistical testing in non-interventional studies

Statistical testing in non-interventional studies

In this article we would like to address the question whether it is useful to perform statistical testing in the context of a NIS, as it is often requested by the sponsor, and why, if tests are performed, we should handle their results with caution [...]
Statistical testing in non-interventional studies (NIS)

Statistical testing in non-interventional studies (NIS)

In this article we would like to address the question whether it is useful to perform statistical testing in the context of a NIS, as it is often requested by the sponsor, and why, if tests are performed, we should handle their results with caution.
The development of an electronic Case Report Form (eCRF)

The development of an electronic Case Report Form (eCRF)

The electronic case report from (eCRF) played a pioneering role in the digitalization and introduction of ever new technologies into clinical research, and enjoys great popularity. Advantages like the availability of your data at all times, the rapid transfer of data also from external devices, automated alerting processes, predefined plausibility checks, and the possibility to use the EDC system as an information sharing platform, speak in favor of the eCRF within clinical and non-interventional studies.

Here, we would like to give you a short overview of how an eCRF develops in the course of a study.

eCRF development for clinical studies and non-interventional studies

© Gstudio Group / Fotolia.com

1. The data management plan

At the very beginning of any data management involvement in the study, a data management plan is created in order to define the scope, standard operating procedures (SOPs), the respective templates and the responsibilities for data management procedures within a study.

2. The structure and data validation plan

The development of an eCRF itself starts with the final study protocol. As soon as the aim of the study and its contents are determined, the structure of the eCRF can be defined, i.e. the names and characteristics of all CRF items and corresponding database tables. For that purpose, a structure plan is created which is reviewed and approved – by all involved parties – before set-up and validation of the eCRF structure within the development environment of the EDC system.

Once the structure of the eCRF is finalized, the criteria for online and offline plausibility checks are defined. Additionally, conditions for E-mail alerts are specified (e.g. adverse event alerts, alerts if a patient is screened / randomized). Therefore, the finalized structure plan is amended with the data validation plan. Upon review and approval of the data validation plan by all involved parties, the implementation and validation of the online edit checks and E-mail alerts can be performed within the development environment of the EDC system.

3. Reports

To facilitate ongoing study and patient management, study-specific status reports are programmed and validated on demand (e.g. patient status by country, query report, adverse event listing).

4. Workflow definition

Apart from the structure and check criteria within the EDC system, it is important to define the project-specific EDC roles, their individual rights and workflows (e. g. who is allowed to enter / read / modify data, to raise / answer queries, to sign the eCRF).

For that purpose, the workflow definition document is created and, upon review and approval by all involved parties, the workflow is implemented and validated within the development environment of the EDC system.

5. User acceptance testing

Before Go-Live, the EDC system is tested for functionality and usability by test users who are, preferably, not familiar with the respective eCRF. The user acceptance test is an overall test to check if the eCRF fits its purpose. Therefore, all system components related to practice are tested (e.g. data entry, monitoring, query process).

Findings and comments have to be documented by each testing person within the user acceptance test report. These findings are reviewed and the intended solutions are documented within the user acceptance test report. Afterwards the corrections and changes are implemented in the EDC system and validated, if applicable.

6. Release of the EDC system / Go-Live

As a last step before Go-Live, once the EDC system is approved by all involved parties, the EDC system is transferred from the development environment to the productive environment.

7. User and access management

In order to get access to the productive environment of the EDC system, all users of the EDC system must be trained in handling the EDC system in their corresponding role. The training requirements are described in the data management plan.

Usually, also user manuals are created within the project-specific EDC system, in accordance with the different existing user roles (e.g. investigator, monitor). After review and approval by all involved parties, the manuals are handed out to the users of the EDC system. They may also be introduced to the users on the welcome page within the EDC system for download.

8. External electronic data – if applicable

Sometimes, external laboratory data or data from an electronic patient-reported outcome (ePRO) have to be incorporated within the eCRF. If study data are transmitted in electronic form from external data providers, project-specific details of external data transfer and import are described in the data management plan. The data transfer specifications (DTS) describe the content, structure and frequency of the external electronic study data transfers.

The DTS are created in collaboration with the external data provider before the first planned data transfer occurs. In order to check compliance with the DTS and technical feasibility, a test data transfer should be performed before the first planned data transfer. External data have to be imported into the study database either directly within the EDC system, or integrated within the exported database. If external data has to be imported directly within the EDC system, an interface has to be programmed and validated within the development environment of the EDC system.

eCRF development for clinical studies and non-interventional studies

© Gstudio Group / Fotolia.com

In case of any questions on this subject, please do not hesitate to contact us! Our experienced data managers are happy to support you with the development of an eCRF tailored to your needs and the requirements of your study.
Your GKM Data Management Team

The development of an electronic Case Report Form (eCRF)

The development of an electronic Case Report Form (eCRF)

The electronic case report from (eCRF) played a pioneering role in the digitalization and introduction of ever new technologies into clinical research, and enjoys great popularity. Here, we would like to give you a short overview of how an eCRF develops in the course of a study.
Typisierungsaktion

Typisierungsaktion

Spender gesucht!

In Deutschland erhält alle 45 Minuten ein Patient die Diagnose Leukämie. Über 75% dieser Menschen kann durch eine Stammzellentransplantation das Leben gerettet werden – jedoch sucht derzeit jeder fünfte Patient vergeblich nach einem passenden Spender. Dies zu ändern, ist Anliegen und Arbeit der Aktion Knochenmarkspende Bayern (AKB, zur Homepage).

Mari Dworznik, Projektmanagerin bei GKM und schon mehrere Jahre ehrenamtlich bei der AKB tätig, machte bei GKM auf die Bedeutsamkeit der Arbeit der AKB aufmerksam. Nur durch die Neuaufnahme von potentiellen Spendern in die Spenderdatei kann Patienten eine Chance auf Heilung gegeben werden. Daher freuen wir uns umso mehr, die AKB nun mit einer eigenen Aktion unterstützen zu können.

Gemeinsam mit dem Klinikum Rechts der Isar wurde eine Typisierungsaktion ins Leben gerufen, die am 15. April 2016 am Klinikum Rechts der Isar im Institut für Virologie stattfinden wird. Es ist so einfach, einem anderen Menschen in nur fünf Minuten Hoffnung zu schenken. Deshalb die Bitte: Unterstützen Sie unsere Aktion und lassen Sie sich gemeinsam mit unseren Mitarbeitern typisieren!

Alle Informationen zur Aktion und zur Typisierung und Stammzellspende im Allgemeinen finden Sie in unserem Flyer sowie auf der Homepage der Aktion Knochenmarkspende Bayern.

Typisierungsaktion Stammzellspende Leukämie AKB

FAQ zur Klinischen Prüfung mit Medizinprodukten

FAQ zur Klinischen Prüfung mit Medizinprodukten

Viele Hersteller werden vor eine große Herausforderung gestellt, wenn sich im Rahmen der klinischen Bewertung über den Literaturweg herausstellt, dass nicht ausreichend klinische Daten zur Verfügung stehen, um die Konformität mit den Grundlegenden Anforderungen (EU RL 93/42EWG, Anhang I) zu zeigen und somit eine klinische Prüfung erforderlich wird [...]
FAQ zur Klinischen Prüfung mit Medizinprodukten

FAQ zur Klinischen Prüfung mit Medizinprodukten

Viele Hersteller werden vor eine große Herausforderung gestellt, wenn sich im Rahmen der klinischen Bewertung über den Literaturweg herausstellt, dass nicht ausreichend klinische Daten zur Verfügung stehen, um die Konformität mit den Grundlegenden Anforderungen zu zeigen und somit eine klinische Prüfung erforderlich wird.
Patientenbeteiligung, Patientenpräferenz – sind evidente Daten machbar?

Patientenbeteiligung, Patientenpräferenz – sind evidente Daten machbar?

Zusatznutzen - eine einfache Gegenrechnung? Die Entwicklung neuer Arzneimittel schreitet kontinuierlich voran, mit dem steten Ziel, die Situation des Patienten zu verbessern, ja im besten Falle, den Patienten zu heilen. Der erhoffte Zusatznutzen eines jeden neuen Arzneimittels wird in Deutschland dabei anhand der Kategorien [...]
Evidence based data, Patientenbeteiligung & Patientenpräferenz – sind evidente Daten machbar?

Evidence based data, Patientenbeteiligung & Patientenpräferenz – sind evidente Daten machbar?

Die Entwicklung neuer Arzneimittel schreitet kontinuierlich voran, mit dem steten Ziel, die Situation des Patienten zu verbessern. Die einfache Gegenrechnung nutzentragender Parameter im Zuge der Zusatznutzenverhandlungen in Deutschland wirft bei näherer Betrachtung eine Reihe an Grundsatzfragen auf.
Old drugs, new tricks

Old drugs, new tricks

Drug development has always been a winding road full of twists and turns. This still holds true nowadays, when we claim to understand the drugs’ methods of actions better than ever. Yet, unexpected discoveries [...]
Old drugs, new tricks

Old drugs, new tricks

Unexpected discoveries in the various stages of drug development are still rather the norm than the exception. Unexpected drug effects are not limited to only adverse drug reactions. Some effects turn out to be beneficial, or even to be an unexpected breakthrough in the treatment of another disease.
More than a gut feeling - our experience in clinical research on Inflammatory Bowel Diseases

More than a gut feeling - our experience in clinical research on Inflammatory Bowel Diseases

Today we would like to start off “Lessons Learned” with inflammatory bowel diseases, a group of indications which we have accompanied for 25 years. Insights from [...]
Gratulation zum Bayerischen Gesundheits- und Pflegepreis 2015

Gratulation zum Bayerischen Gesundheits- und Pflegepreis 2015

Innovativste Projekte im Bereich Gesundheit & Pflege - In diesem Jahr verlieh Bayerns Gesundheitsministerin Melanie Huml zum ersten Mal den mit 5000 Euro dotierten Bayerischen Gesundheits- und Pflegepreis 2015. Im Kaisersaal der Residenz in München erhielten aus den insgesamt 163 nominierten Projekten drei herausragende Projekte [...]
Pragmatismus gefragt – Herausforderungen und Chancen für die klinische Forschung im Zeitalter der frühen Nutzenbewertung in Deutschland

Pragmatismus gefragt – Herausforderungen und Chancen für die klinische Forschung im Zeitalter der frühen Nutzenbewertung in Deutschland

Harsche Pharma-Kritik - Bereits zum dritten Mal erschien im September dieses Jahres der Innovationsreport der Techniker Krankenkasse. Wie in den vorausgegangenen Ausgaben analysieren darin Experten um den Bremer Professor Gerd Glaeske die Verordnungszahlen neuer Medikamenten [...]
Pragmatismus gefragt – Herausforderungen und Chancen für die klinische Forschung im Zeitalter der frühen Nutzenbewertung in Deutschland

Pragmatismus gefragt – Herausforderungen und Chancen für die klinische Forschung im Zeitalter der frühen Nutzenbewertung in Deutschland

In einer Hinsicht sind sich Interessenvertreter der Industrie und der Kostenträger einig – das Arzneimittel-Neuordnungs-Gesetz habe sein Ziel verfehlt. Doch was haben wir gelernt?
Listen to your eye

Listen to your eye

The Eye – gateway to medical insight. - The eye is not only our window to the world. Reversing perspectives, it also serves as a valuable access point to examine the human body inside out. Indeed, a look through the pupil provides insight into a patient’s overall health status [...]
Listen to your eye

Listen to your eye

The eye is not only our window to the world. Reversing perspectives, it also serves as a valuable access point to examine the human body inside out. Indeed, a look through the pupil provides insight into a patient’s overall health status!

Kontaktinformation

Lessingstraße 14 80336 München

Phone: +49 89 209120 0

Fax: +49 89 209120 30

Web: www.gkm-therapieforschung.de